Cleveland Clinic | Strategic Alliance Partners

March 23, 2023

A brief review of sequencing patterns in urothelial carcinoma and the typical number of lines of therapy a patient may receive.

March 23, 2023

A panel of four key opinion leaders share real-world urothelial carcinoma practice patterns at their respective institutions.

March 23, 2023

Cleveland Clinic has opened a new state-of-the-art cancer facility, named the Fatima bint Mubarak Center, at Cleveland Clinic Abu Dhabi.

March 22, 2023

A review of systemic treatment options used in polycythemia vera and the roles these play in the current treatment landscape.

March 22, 2023

A brief overview of myeloproliferative neoplasms and the associated signs and symptoms commonly presenting in patients.

March 14, 2023

Adjuvant osimertinib and other targeted therapies, such as KRAS G12C inhibitors, could continue to change the perioperative treatment landscape in non–small cell lung cancer.

March 14, 2023

Craig Sauter, MD, discusses where BTK inhibitors could fit into the frontline treatment landscape for patients with central nervous system lymphoma and research aiming to address other unmet needs for this patient population.

March 07, 2023

The advent of effective first-generation TKIs has allowed for improvements among patients with Philadelphia chromosome–positive disease, which is traditionally associated with a poor prognosis, as it generally does not respond to conventional chemotherapy options.

March 03, 2023

Khaled Hassan, MD, discusses the importance of performing precise molecular profiling in patients with lung cancer and the need to identify individually tailored treatment approaches.

February 28, 2023

To increase access to emerging cancer therapeutics and improve convenience for patients and researchers, Taussig Cancer Institute opened a dedicated Novel Therapeutics Clinic.

February 23, 2023

Pradnya D. Patil, MD, FACP, discusses unmet needs that remain to be addressed with the use of immunotherapy in patients with non–small cell lung cancer.

February 14, 2023

Shared insight on recently updated data in acute myeloid leukemia following the ASH 2022 annual meeting.

February 14, 2023

Experts in hematologic oncology review and analyze updated data in chronic myeloid leukemia from ASH 2022.

February 14, 2023

Following the ASH 2022 Annual Meeting, hematologic oncology experts discuss updated data in acute lymphocytic leukemia.

February 02, 2023

Julie Lang, MD, discusses potential applications for the Parsortix® PC1 system in metastatic breast cancer.

January 27, 2023

Despite American Society of Clinical Oncology guidelines calling for introduction of palliative care early in the course of disease, these services remain underused.

January 25, 2023

Daniel Rotroff, PhD, discusses the investigation of biomarkers that could help identify patients with breast cancer who are at risk for developing chemotherapy-induced peripheral neuropathy.

January 23, 2023

Craig Sauter, MD, discusses the rationale for investigating maintenance pembrolizumab following autologous stem cell transplant in patients with T-cell NHL and explained some of the potential challenges of investigating this regimen in a larger prospective trial in this patient population.

January 05, 2023

Megan Kruse, MD, discusses how socioeconomic disparities and access to health insurance can contribute to poorer overall survival (OS) outcomes in adolescent patients with invasive breast cancer.

January 04, 2023

Craig Sauter, MD, discusses important considerations regarding the use of pembrolizumab after autologous stem cell transplant in T-cell non-Hodgkin lymphoma.